Q-omics provides the consensus-scored RAP2CP1 profile across patient tissues and cancer cell-line models. RAP2CP1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RAP2CP1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, RAP2CP1 RNA expression shows 11,886 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where RAP2CP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAP2CP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAP2CP1 survival associations across molecular data types. RAP2CP1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAP2CP1 RNA expression–survival associations across cancer types. High RAP2CP1 expression shows unfavorable associations in LUAD and COAD, but favorable associations in HNSC, MESO, KIRC and SARC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RAP2CP1 RNA expression.
This table summarizes RAP2CP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RAP2CP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAP2CP1 shows lower tumor expression in KICH, THCA and KIRP and higher tumor expression in LUSC, BRCA and STAD. The KICH box plot shows higher RAP2CP1 RNA expression in normal versus tumor tissue (log2 FC = −1.500, t-test p < 0.001).
This table shows molecular features associated with RAP2CP1 in patient tissues and cancer cell lines. In patient samples, RAP2CP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
